Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vertex Is The First To Get NaV1.8 To Proof Of Concept For Pain

Effort Is Built On Decades Of Sodium Channel Research

Executive Summary

Chief scientific officer David Altshuler talked to Scrip about the late-stage development plan for a drug that could represent a blockbuster-sized commercial opportunity, after two Phase II studies testing VX-548 met their primary endpoints.

You may also be interested in...



As AbbVie’s Challenge Falters, Vertex Looks To Build On CF Dominance

Vertex is likely to have the cystic fibrosis market to itself for years to come, but investors are banking on it repeating that success in several new first-in-class therapy areas.

Vertex Diabetes Cell Therapy Trial On Hold – As First Patient Free From Insulin Injections

Vertex expresses surprise at the US FDA’s call for a halt, as it reveals an exciting milestone reached - the first trial participant now producing their own insulin.

Pfizer/Lilly Discontinue Tanezumab, The Likely End For A Class Dogged By Safety

The nerve growth factor inhibitor for osteoarthritis pain is one of the last still in development after safety largely sidetracked the class of drugs.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel